Sibutramine on cardiovascular outcome

Diabetes Care

Volumn 34, Issue SUPPL. 2, 2011, Pages

  Scheen, André J ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; LIPID; SIBUTRAMINE; ANOREXIGENIC AGENT; CYCLOBUTANE DERIVATIVE;

BEHAVIOR CHANGE; BODY MASS; CARDIOVASCULAR RISK; DIET THERAPY; DISEASE ASSOCIATION; DRUG CONTRAINDICATION; DRUG FATALITY; DRUG LABELING; DRUG SAFETY; DRUG WITHDRAWAL; DYSLIPIDEMIA; ELECTROCARDIOGRAPHY; EUROPEAN UNION; EXERCISE; FOOD AND DRUG ADMINISTRATION; GLYCEMIC CONTROL; HEART ARRHYTHMIA; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; ISCHEMIC HEART DISEASE; LIFESTYLE MODIFICATION; MEDICAL DECISION MAKING; MORBIDITY; MORTALITY; OBESITY; PATIENT MONITORING; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR; STROKE; TACHYCARDIA; TREATMENT OUTCOME; UNITED STATES; WEIGHT REDUCTION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR SYSTEM; CHEMICALLY INDUCED DISORDER; DRUG EFFECT;

APPETITE DEPRESSANTS; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; CYCLOBUTANES; HUMANS;

EID: 79959783306     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc11-s205     Document Type: Review

References (51)

1. Klein S, Burke LE, Bray GA, et al.; American Heart Association Council on Nutrition, Physical Activity, and Metabolism. Clinical implications of obesitywith specific focus on cardiovascular disease: a statement for professionals from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: endorsed by the American College of Cardiology Foundation. Circulation 2004;110:2952-2967 (Pubitemid 39473623)
2. Poirier P, Giles TD, Bray GA, et al.; American Heart Association; Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation 2006;113: 898-918
3. Van Gaal LF, Mertens IL, De Block CE. Mechanisms linking obesity with cardiovascular disease. Nature 2006;444:875-880 (Pubitemid 46028447)
4. Zalesin KC, Franklin BA, Miller WM, Peterson ED, McCullough PA. Impact of obesity on cardiovascular disease. Endocrinol Metab Clin North Am 2008;37: 663-684, ix
5. Douketis JD, Sharma AM. Obesity and cardiovascular disease: pathogenic mechanisms and potential benefits of weight reduction. Semin Vasc Med 2005;5: 25-33 (Pubitemid 40721042)
6. Bodary PF, Iglay HB, Eitzman DT. Strategies to reduce vascular risk associated with obesity. Curr Vasc Pharmacol 2007; 5:249-258
7. Scheen AJ. Current management strategies for coexisting diabetes mellitus and obesity. Drugs 2003;63:1165-1184 (Pubitemid 36750949)
8. Lavie CJ, Milani RV, Ventura HO. Obesity and cardiovascular disease: risk factor, paradox, and impact of weight loss. J Am Coll Cardiol 2009;53:1925-1932
9. Ioannides-Demos LL, Proietto J, McNeil JJ. Pharmacotherapy for obesity. Drugs 2005;65:1391-1418 (Pubitemid 41043893)
10. Hofbauer KG, Nicholson JR, Boss O. The obesity epidemic: current and future pharmacological treatments. Annu Rev Pharmacol Toxicol 2007;47:565-592
11. Heal DJ, Gosden J, Smith SL. Regulatory challenges for new drugs to treat obesity and comorbid metabolic disorders. Br J Clin Pharmacol 2009;68:861-874
12. Greenway FL, Caruso MK. Safety of obesity drugs. Expert Opin Drug Saf 2005;4: 1083-1095 (Pubitemid 41671605)
13. McNeely W, Goa KL. Sibutramine: a review of its contribution to the management of obesity. Drugs 1998;56:1093-1124 (Pubitemid 29010230)
14. Nisoli E, Carruba MO. An assessment of the safety and efficacy of sibutramine, an anti-obesity drug with a novel mechanism of action. Obes Rev 2000;1:127-139
15. Sharma B, Henderson DC. Sibutramine: current status as an anti-obesity drug and its future perspectives. Expert Opin Pharmacother 2008;9:2161-2173
16. Tziomalos K, Krassas GE, Tzotzas T. The use of sibutramine in the management of obesity and related disorders: an update. Vasc Health Risk Manag 2009;5:441-452
17. Arterburn DE, Crane PK, Veenstra DL. The efficacy and safety of sibutramine for weight loss: a systematic review. Arch Intern Med 2004;164:994-1003 (Pubitemid 38581520)
18. Norris SL, Zhang X, Avenell A, et al. Efficacy of pharmacotherapy for weight loss in adults with type 2 diabetes mellitus: a meta-analysis. Arch Intern Med 2004; 164:1395-1404 (Pubitemid 38937850)
19. James WP, Astrup A, Finer N, et al. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance. Lancet 2000; 356:2119-2125
20. Filippatos TD, Kiortsis DN, Liberopoulos EN, Mikhailidis DP, Elisaf MS. A review of the metabolic effects of sibutramine. Curr Med Res Opin 2005;21:457-468
21. Scheen AJ, Paquot N. Pharmacological treatment of obesity, food intake, and reversal of metabolic disorders. Curr Nutr Food Sci 2007;3:123-133 (Pubitemid 46773888)
22. Scheen AJ, Ernest PH. New antiobesity agents in type 2 diabetes: overview of clinical trials with sibutramine and orlistat. Diabetes Metab 2002;28:437-445 (Pubitemid 36077145)
23. Vettor R, Serra R, Fabris R, Pagano C, Federspil G. Effect of sibutramine on weight management and metabolic control in type 2 diabetes: a meta-analysis of clinical studies. Diabetes Care 2005;28: 942-949 (Pubitemid 40434504)
24. Haynes WG, Egri Z. Sibutramine and the sympathetic nervous system in obese humans. Clin Auton Res 2005;15:189-192 (Pubitemid 40909706)
25. de Simone G, Romano C, De Caprio C, et al. Effects of sibutramine-induced weight loss on cardiovascular system in obese subjects. Nutr Metab Cardiovasc Dis 2005; 15:24-30 (Pubitemid 40546030)
26. de Simone G, D'Addeo G. Sibutramine: balancing weight loss benefit and possible cardiovascular risk. NutrMetabCardiovasc Dis 2008;18:337-341
27. Nisoli E, Carruba MO. A benefit-risk assessment of sibutramine in the management of obesity. Drug Saf 2003;26: 1027-1048 (Pubitemid 37452644)
28. Ioannides-Demos LL, Proietto J, Tonkin AM, McNeil JJ. Safety of drug therapies used for weight loss and treatment of obesity. Drug Saf 2006;29:277-302
29. Kim SH, Lee YM, Jee SH, Nam CM. Effect of sibutramine on weight loss and blood pressure: a meta-analysis of controlled trials. Obes Res 2003;11:1116-1123
30. Horvath K, Jeitler K, Siering U, et al. Longterm effects of weight-reducing interventions in hypertensive patients: systematic review and meta-analysis. Arch Intern Med 2008;168:571-580 (Pubitemid 351468391)
31. Johansson K, Sundström J, Neovius K, Rössner S, NeoviusM. Long-termchanges in blood pressure following orlistat and sibutramine treatment: a meta-analysis. Obes Rev 2010;11:777-791
32. Florentin M, Liberopoulos EN, Elisaf MS. Sibutramine-associated adverse effects: a practical guide for its safe use. Obes Rev 2008;9:378-387 (Pubitemid 351842191)
33. Bosello O, Carruba MO, Ferrannini E, Rotella CM. Sibutramine lost and found. Eat Weight Disord 2002;7:161-167
34. Wooltorton E. Obesity drug sibutramine (Meridia): hypertension and cardiac arrhythmias. CMAJ 2002;166:1307-1308 (Pubitemid 34533957)
35. Harrison-Woolrych M, Clark DW, Hill GR, Rees MI, Skinner JR. QT interval prolongation associated with sibutramine treatment. Br J Clin Pharmacol 2006;61: 464-469
36. Ernest D, Gershenzon A, Corallo CE, Nagappan R. Sibutramine-associated QT interval prolongation and cardiac arrest. Ann Pharmacother 2008;42:1514-1517
37. Azarisman SM, Magdi YA, Noorfaizan S, Oteh M. Myocardial infarction induced by appetite suppressants in Malaysia. N Engl J Med 2007;357:1873-1874 (Pubitemid 350044825)
38. Yim KM, Ng HW, Chan CK, Yip G, Lau FL. Sibutramine-induced acute myocardial infarction in a young lady. Clin Toxicol (Phila) 2008;46:877-879
39. Eroglu E, Gemici G, Bayrak F, Kalkan AK, Degertekin M. Acute myocardial infarction in a 24 year-old man possibly associated with sibutramine use. Int J Cardiol 2009;137:e43-e45
40. Gómez-Barrado JJ, Turégano S, Garcipérez de Vargas FJ, Porras Y. Acute coronary syndrome in a young woman treated with sibutramine. Rev Esp Cardiol 2010;63:243
41. Seebeck J, Wulf F, Sachs B. Labelinconsistent use of sibutramine in spontaneous adverse drug reaction reports in Germany. Int J Clin Pharmacol Ther 2008; 46:375-381 (Pubitemid 352005930)
42. Dahlin A, Beermann B. Incorrect use of orlistat and sibutramine in clinical practice. Eur J Clin Pharmacol 2007;63:205-209 (Pubitemid 46147063)
43. James WPT. The SCOUT study: riskbenefit profile of sibutramine in overweight high-risk cardiovascular patients. Eur Heart J 2005;7(Suppl. L):L44-L48 (Pubitemid 41630392)
44. Torp-Pedersen C, Caterson I, Coutinho W, et al.; SCOUT Investigators. Cardiovascular responses to weight management and sibutramine in high-risk subjects: an analysis fromthe SCOUT trial. Eur Heart J 2007;28:2915-2923 (Pubitemid 350233016)
45. Sharma AM, Caterson ID, Coutinho W, et al.; SCOUT Investigators. Blood pressure changes associated with sibutramine and weight management: an analysis from the 6-week lead-in period of the Sibutramine Cardiovascular Outcomes Trial (SCOUT). Diabetes Obes Metab 2009;11: 239-250
46. Van Gaal LF, Caterson ID, Coutinho W, et al.; SCOUT Investigators. Weight and blood pressure response to weight management and sibutramine in diabetic and non-diabetic high-risk patients: an analysis from the 6-week lead-in period of the Sibutramine Cardiovascular Outcomes (SCOUT) trial. Diabetes Obes Metab 2010; 12:26-34
47. Maggioni AP, Caterson I, Coutinho W, et al.; SCOUT Investigators. Tolerability of sibutramine during a 6-week treatment period in high-risk patients with cardiovascular disease and/or diabetes: a preliminary analysis of the Sibutramine Cardiovascular Outcomes (SCOUT) Trial. J Cardiovasc Pharmacol 2008;52:393-402
48. Caterson I, Coutinho W, Finer N, et al.; SCOUT Investigators. Early response to sibutramine in patients not meeting current label criteria: preliminary analysis of SCOUT lead-in period. Obesity (Silver Spring) 2010;18:987-994
49. von Haehling S, Lainscak M, Anker SD. Sibutramine in cardiovascular disease: is SCOUT the new STORM on the horizon? Eur Heart J 2007;28:2830-2831 (Pubitemid 350233044)
50. James WP, Caterson ID, Coutinho W, et al.; SCOUT Investigators. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med 2010;363:905-917
51. Williams G.Withdrawal of sibutramine in Europe. BMJ 2010;340:c824